Katherine Al-Kadhimi

发表

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Andrew P Thomas, C. Rooney, E. Kilgour, 2012, Cancer research.

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.

S. Barry, J. Kendrew, D. Cross, 2012, Bioorganic & medicinal chemistry letters.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

William Pao, Peter Ballard, Hailing Jin, 2014, Cancer discovery.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon

J. Barrett, T. French, Paul D. Smith, 2016, PloS one.

Abstract 3568: Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3

Andrew P Thomas, E. Kilgour, T. Klinowska, 2011 .

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

Andrew P Thomas, C. Rooney, E. Kilgour, 2012, Cancer research.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

W. Pao, M. Ranson, Hailing Jin, 2014, Cancer discovery.

Azd9291, an Irreversible Egfr Tki, Overcomes T790m-mediated Resistance to Egfr Inhibitors in Lung Cancer Oncology Innovative Medicines And

W. Pao, D. Cross, R. Rowlinson, 2022 .